Research & Development
Hansa Biopharma signs EUR115m IDEFIRIX licensing deal with SERB
19 May 2026 - Swedish biotechnology company Hansa Biopharma AB (STO:HNSA) announced on Tuesday an exclusive licensing agreement with specialty pharmaceutical company SERB S.A. for the development and ...
Lupin receives tentative FDA approval for Revefenacin Inhalation Solution
19 May 2026 - Global pharmaceutical company Lupin Limited (BSE:500257) (NSE:LUPIN) announced on Monday that it the US Food and Drug Administration (FDA) has granted tentative approval for its Abbrevia...
Artivion completes acquisition of Endospan following FDA approval of NEXUS Aortic Arch System
18 May 2026 - Endospan, a pioneer in endovascular solutions for complex aortic pathologies, announced on Monday that it has been acquired by medical device company Artivion Inc (NYSE: AORT) following ...
AstraZeneca wins US approval for Baxfendy as first aldosterone synthase inhibitor for hypertension
18 May 2026 - Biopharmaceutical company AstraZeneca plc (LSE: AZN) (STO: AZN) (NYSE: AZN) reported on Monday that it has received US Food and Drug Administration approval for Baxfendy (baxdrostat), th...
Akeso reports results from Phase II trial of ligufalimab combination therapy in AML
18 May 2026 - Biopharmaceutical company Akeso Inc (HK:9926) announced on Friday that results from its randomised, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) wil...
US FDA approves Datar Cancer Genetics' comprehensive genomic profiling assay for solid tumours
15 May 2026 - Precision oncology company Datar Cancer Genetics (DCG) announced on Thursday that the US Food and Drug Administration (FDA) has cleared its tissue-based comprehensive genomic profiling (...